IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Review on "Pharmacovigilance Is A Growing And Important Sector In The Pharmaceutical Field"

[1] Mr.Siddharth R. pathare. [2] Ms.Nilam S. Bankar. [3]Ms.Sneha K. Pathare.

[4]Mr.Mayur P. Weljali. [5]Tejas S. Ghogare.

[1] Student at LSDP College of Pharmacy, Mandavgan Pharata, Shirur, Pune.

[2] Student at LSDP College of Pharmacy, Mandavgan Pharata, Shirur, Pune.

[3] Student at LSDP College of Pharmacy, Mandavgan Pharata, Shirur, Pune.

[4] Student at LSDP College of Pharmacy, Mandavgan Pharata, Shirur, Pune.

[5] Student at LSDP College of Pharmacy, Mandavgan Pharata, Shirur, Pune.

ABSTRACT: - Pharmacovigilance defined by the World Health Organization as "the science and activities relating to the collection, detection, assessment, understanding and interference of adverse effects or the other medication or vaccines related problem". It additionally called the drug safety. The pharmacovigilance word comes from Greek word pharmakon (drug) and Latin word vigilare (keep watch).It is supported the adverse drug reaction. It outline as "an appreciably harmful or unpleasant reaction, ensuing from Associate in Nursing intervention associated with the utilization of a meditative product, that predicts hazard from future administration and warrants interference or specific treatment, or alteration of the dose program, or withdrawal of the merchandise. The most aim of pharmacovigilance is to enhance patient care and safety in respect to the utilization of medicines and every one medical and paramedical intervention, improve public health and safety in respect to the utilization of medicines and find issues associated with the utilization of medicines. The history of Pharmacovigilance started 169 years ago, on Jan 29, 1848, once a young woman (Hannah Greener) from the north of European nation died once receiving chloroform Associate in Nursingesthetic before removal of an infected toenail. In 1961, a giant modification of European Pharmacovigilance happened following the tragedy of sedative-hypnotic drug. Dr. McBride, Associate in Nursing Australian doctor, wrote a letter to the editor of the Lancet Journal, during which he recommended a association between no inheritable malformation of babies and sedative-hypnotic drug. From Apr 2011, IPC, Ghaziabad took over because the National coordinative Centre (NCC) for PvPI with adverse drug reactions (ADRs) being rumored from all across the country to NCC-PvPI. Under PvPI, numerous medical faculties began to operate as adverse drug reaction observance Centre (AMCs) for assembling suspected ADR reports and forwarding them to NCC for more analysis. The principal goal of pharmacovigilance is to influence

patients and health care professionals to use medicines a lot of safely. Corporations pay billions of bucks on PV each year hoping to realize specifically that. Nevertheless adverse drug reactions stay a serious explanation for death.

KEYWORDS: - Adverse reaction, Drug, Drug safety, Patient, Pharmacovigilance, Report.

INTRODUCTION: - Consuming a drug is equivalent to consume a risk. It is only when the benefit associated with the drugs are more than the risk, that the consumption of a drug is justified. Thus, it is benefit versus risk ratio of the drug which decides whether a drug is to be taken or not. This main work is done by the pharmacovigilance department. So it is defined as the science and activities related to the detection, assessment, understanding and prevention of adverse effects or any other possible drug-related problems. The second edition of An Introduction to Pharmacovigilance describes the pharmacovigilance organization of health systems worldwide and, in particular, in the United States and Europe. The authors of the second edition of this guide have considerable experience in the field of pharmacovigilance.

History and development of Pharmacovigilance: -

Pharmacovigilance started about 170 years ago, although it was not yet named as such at that time. It is structured activity in the professional health field, with important social and commercial implications. Which has aimed at determine the risk/benefit ratio of drugs, improving patient's safety and care of the patient and the quality of life. During the 20th century there were some serious adverse events associated with the medical products and drugs that resulted in pressure on governments, businesses to produce legalization and guidance, as well as the evolution of the regulatory bodies to protect the safety of patients. Then the pharmacovigilance is started. On Jan 29, 1848.then a young girl from the north of England died after receiving chloroform anesthetic before removal of infected toenail. Then in 1937, there were 107 deaths in the USA, because of the use of sulfanilamide elixir, containing diethyl glycol as the solvent, the Federal Food, Drug and Cosmetic Act was established in 1938. Its aim was to promote the public health system. Then Thalidomide tragedy comes in a picture in 1961-1962, Thalidomide is introduced as the safe and effective hypnotic and anti-emetic. It has rapidly popular in the treatment of the nausea and vomiting in pregnancy, but this drug affect on the potent human teratogen that causes the birth defect in 10,000 of children's. Dr. M. C. Bride suggested the link between birth abnormality and Thalidomide then the development is started. Many countries set a standard in which any new drugs were required to meet before getting authorization for marketing.

Important years of development of the pharmacovigilance:-



Fig.No.1

Aims of pharmacovigilance:-

1) To improve patient care and safety.

2) To improve public health and safety.

3) To contribute to the assessment of benefit, harm, effectiveness, and risk of medicines.

4) To promote education and clinical training.

5) To promote effective communication to the public.

6) To promote rational and safe use of medicines.

7) Early detection of the adverse drug reaction.

8) Estimation of quantitative aspect of benefit and risk.

Objectives of Pharmacovigilance:-



Fig. No. 2

Importance of Pharmacovigilance: -

Pharmacovigilance is arguably the foremost essential perform inside a natural science company. To develop, manufacture and commercialese a drug an organization should adhere to strict rules. Several of those rules can specialize in the patient's safety and also the additional benefit to the patient derived from the drug. This, in a very shell, is that the mission of drug safety and highlights why this discipline plays such a central and necessary role inside prescription drugs.

●Complete safety information will solely be captured through Pharmacovigilance.

●It will be captured through clinical trials that square measure conducted beneath pharmacovigilance.

●Promote the rational use of the medicines.

Important terms in pharmacovigilance:-

1) Adverse drug reaction: - An adverse drug reaction (ADR) can be defined as 'an appreciably harmful or unpleasant reaction resulting from an intervention related to the use of a medicinal product.

2) Adverse event: - An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administrated a pharmaceutical product and which does not necessarily have a causal relationship with treatment.

3) Serious adverse event: - Serious Adverse Events include adverse events that result in death, require hospitalization or the prolongation of hospitalization, are life-threatening event, result in a disability or result in a congenital anomaly/birth defect.

4) Causal relationship: - A causal relationship exists when one variable in a data set has a direct affect on another variable.

5) Dechallenge and Rechallenge: - Dechallenge is refer to a drug being stopped and Rechalange is refers to the restarted in the patient. A positive Dechallenge has observed when an adverse event abates or resolves completely following the drug's discontinuation. A positive rechallenge has observed, when the adverse event re-occurs after the drug is restarted. Dechallenge and rechallenge have important role in determining whether a causal relationship between an event and a suspected drug.

6) Signal: - Signal is new information within safety data that requires further investigation.

7) Individual Case Safety Report (ICSR):- A document providing information related to an individual case of a suspected side effect due to a suspected product.

8) Triage: - It is the process of placing a potential adverse event reported in to the three different categories. Serious case, non- serious case and no case.

9) Periodic safety update report (PSUR):- Format and content for providing an evaluation of the balance between risk and benefits of a medicinal product for submission by the marketing authorization holder at defined time points during the post-authorization phase.

10) Signal Management: - A signal management process is a set of activities performed to determine whether there are new risks associated with an suspected drug or a medicinal product and includes any related recommendations, decisions, communications and tracking.

International collaboration in the field of Pharmacovigilance: -

The Uppsala Monitoring Centre (UMC) was the first WHO Collaborating Centre to be established for pharmacovigilance, in 1978, the scientific and technical responsibility of the WHO Programme for International Drug Monitoring was transferred to Sweden. United States Food and Drug Administration (FDA): It work as sharing information on drug safety issues and on anticipated regulatory action, public information and communication prior to decision-making and publication. In the European Union the European Medicines Evaluation Agency is work for the pharmacovigilance department. Egyptian pharmacovigilance centers are also collaborate with the Pharmacovigilance.

WHO Pharmacovigilance programme:-

In 1968, during the 16th World Assembly the resolution called for "a systematic collection of information on serious adverse drug reactions during the development and particularly after medicines have been made available for public use". This led to the formation of the WHO Programme for International Drug Monitoring in 1978. WHO promotes PV at country level. Initially the WHO PIDM members consisted of 10 countries. As of March 2022, there is 151 members are in the WHO PIDM, and in addition 21 associate members are awaiting full membership. India is the full member of the WHO Pharmacovigilance programme.

Working:-

1) Identification and analysis of Adverse drug reactions signals from national centers and sent to the WHO ICSR database.

2) Provision of the WHO database as the reference source.

3) Information exchange between WHO UMC national centers through vigimed.

4) Publication of news and guidelines and new books in Pharmacovigilance.

5) Supply tools to the national centers, e.g. WHO Drug Dictionary.

6) Training to the national centers.

Pharmacovigilance Programme of India: -

The Pharmacovigilance Programme of India (PvPI) is an Indian government organization which observe and responds to drug safety problems. Its activities include receiving reports of adverse drug events and taking required action to these problems. The Central Drugs Standard Control Organisation established the present Pharmacovigilance Program of India in 2010. Now the program is well integrated with government permission, and a research center as part of the Indian Pharmacopoeia Commission. Which is located at Ghazaiabad.



Fig.No.3

Process of data management in the Pharmacovigilance: -

The pharmacovigilance data processing cycle starts with the collection of the data from different sources, then processing of the data in the database, and the medical evaluation of the data is done finally, the reporting is happened.



» Sources of reporting:-

1) Spontaneous reporting:-

An unsolicited communication by a healthcare professional or reporter to a marketing authorization holder, regulatory authority or other organization that describes one or more adverse drug reactions in a patient who was given one or more medicinal products and that does not ask by the company and any organized data collection scheme. Spontaneous reporting is by nature a good to pharmacovigilance, giving reply on the motivation of individuals to report suspected adverse drug reactions to a local or national pharmacovigilance centre.

2) Solicited sources of report: -

As defined in ICH-E2D, solicited reports of suspected adverse reactions are those derived from organised data collection systems, it mean company asking for the data by the clinical trials, non-interventional studies, registries, post-approval named patient use programmes, information from the patient compliance, surveys of patients, compassionate use or name patient use, or information gathering on efficacy or patient compliance.

3) Literature reports: -

The scientific and medical literature may be a important supply of knowledge for the observation of the protection profile and of the risk-benefit balance of medicinal product, notably in respect to the detection of recent safety signals or rising questions of safety. Reports of suspected adverse reactions from the scientific and medical literature, together with relevant revealed abstracts from conferences and draft manuscripts, ought to be reviewed and assessed by selling authorisation holders to spot and record ICSRs originating from spontaneous reports or non-interventional post-authorisation studies.

4) Reports from alternative sources:-

If a selling authorisation holder becomes responsive to a report of suspected adverse reactions originating from a non-medical supply, as an example the lay press or alternative media, it ought to be handled as a spontaneous report. Each try ought to be created to follow-up the case to get the minimum data that constitutes a legitimate ICSR. Constant news time frames ought to be applied as for alternative spontaneous reports.

.

» Case processing in database:-

The role of a case processor is to observe and track all serious adverse events, serious and medically significant adverse drug reactions (ADRs), and other medicinal related product information followed by timely processing and reporting of such information in shear with the company. And this process includes data entry, medical coding, quality control review and medical review.

Steps in the case processing in database-

Fig.No.4

» Process of Signal Detection: -

According to the WHO, signal is defined as "reported information on a possible causal relationship between a suspected adverse event and a suspected drug or product of which the relationship is unknown or not properly documented previously". Pharmacovigilance involves the collection of data on Adverse Reactions which is analysed and evaluated to create safety information. Signal detection in Pharmacovigilance is the collection of adverse reaction data for patterns that suggest new safety information.

How does the signal detected?

Periodic analysis of VigiBase data is performed, in current routine Signal detection process, to find previously unrecognized ADRs. With over 14 million reports in VigiBase, an automated way of selecting drug-ADR combinations for further clinical assessment is required. A selection strategy referred to as the "triage methodology", using a measure of disproportionality between the observed and the expected reporting of a drug-ADR combination and other statistics reduce the number of drug-ADR combinations to assess and more the likelihood of finding the most important signals. UMC's data-mining methodology has been investigated for its predictive capabilities: a positive predictive value of 44% and a negative predictive value of 85%.

Detection of signals may be performed based on a review of ICSRs, from statistical analyses in large databases, or from a combination of both.

Review of individual case safety reports:-

ICSRs may start from a spontaneous reporting system, post- authorisation studies and monitoring of literature. Even a single report of a serious or severe adverse reaction may be sufficient to raise a signal and to take further action.

Statistical analyses:-

Signal detection is now increasingly based on a regular periodic monitoring of huge databases of the reports of ADRs. Such databases allow creation of statistical reports showing information on adverse reactions received over a fix time period for defined active substances or medicinal products. Different methods have been developed to identify statistics of disproportionate reporting.

Fig.No.5

Future of Pharmacovigilance: -

The principal goal of pharmacovigilance is to influence safer usage of medicines. But, it faces increasing pressure to analyze more data faster, monitor risks more accurately, and report patient events of all over the world. As with many areas of the pharmaceutical industry, COVID-19 created significant disruption for pharmacovigilance activities, including post-marketing surveillance. The rapidly growing volume of data along with shifting regulatory and consumer trends due to the COVID-19, forced PV leaders to rethink their typical safety data management processes and PV technology. The global pharmacovigilance market size was valued at USD 6.97 billion in 2021 and is expected to expand at a compound annual growth rate of 10.5% from 2022 to 2030. An increase in the prevalence of chronic diseases such as oncological diseases, diabetes, and cardiovascular and respiratory disorders has led to an increase in drug consumption worldwide. Therefore, the demand for new drug development through the clinical trials has increased. Pharmacovigilance (PV) is the inevitable part of drug discovery and development of the new drug. In future the Pharmacovigilance sector is definitely grown because of the increasing the Importance if the pharmacovigilance, as well as the patient safety is the more important factor in this competitive world. Every pharmaceutical company needs the best Pharmacovigilance department for the patient safety and the development of the new drugs. So the

pharmacovigilance department is very important in the future and the future of pharmacovigilance department is very bright and always growing.

Conclusion:-

To create awareness of the pharmacovigilance as a growing sector in India and world. Give the available information related to the pharmacovigilance, how the Pharmacovigilance department help in patient care and patient safety. Increase awareness about the patient safety and care by giving the information about this department. So we conclude that the pharmacovigilance is the growing sector in India and whole world.

References:-

1) "The Importance of Pharmacovigilance - 2002". Www.paho.org. Retrieved December 31, 2020.

2) Lindquist M. The need for definitions in pharmacovigilance. Drug Safety. 2007;30(10):825-30.

3) Pharmacovigilance. Mann RD, Andrews EB, eds. John Wiley & Sons Ltd, Chichester, 2002.

4) Kalaiselvan V, Prakash J, Singh GN. Pharmacovigilance programme of India. Arch Pharm Pract. 2012;3:229–32.

5) Raut A, Diwan A, Patel C, Patel P, Pawar A. Incidence, severity and financial burden associated with adverse drug reactions in medicine inpatients. Asian J Pharm Clin Res. 2011;4:103–11.

6) World Health Organization (2017). "WHO Collaborating Centre for Pharmacovigilance in Public Health Programmes and Regulatory Services". World Health Organization. Archived from the original on 26 February 2018.

7) Margraff, F. and D. Bertram (2014). "Adverse drug reaction reporting by patients: an overview of fifty countries." Drug Saf 37(6): 409-419.

8) 8 September 2014 EMA/873138/2011 Rev 1* (superseded version) Guideline on good pharmacovigilance practices (GVP) Module VI – Management and reporting of adverse reactions to medicinal products.

9) P LePendu, SV Iyer, C Fairon, NH. Shah Annotation analysis for testing drug safety signals using unstructured clinical notes J Biomed Semantics, 3 (Supplement 1) (2012), p. S5.

10) Aravindhswamy H, Sankar Narayanan R, Manigandan T, Aswath N, Hemalatha VT.Pharmacovigilance, adverse drug reactions and future aspects of pharmacovigilance in India: Areview article. Indian J Public Heal Res Dev. 2019;10(12):1021–5.

11) World Health Organization . Safety monitoring of medicinal products: guidelines for setting up and running a pharmacovigilance centre. Uppsala: Uppsala Monitoring Centre, World Health Organization; 2000.

12) Carmago AL, Cardoso Ferreira MB, Heineck I. Adverse drug reactions: a cohort study in internal medicine units at a university hospital. Eur J Clin Pharmacol. 2006;62:143–149.

13) J.P Loannidis, J Lau. Completeness of safety reporting in randomized trials: an evaluation of seven medical areas. JAMA, 2001; 285(4): 437-443.

14) Edwards IR, Aronson JK. Adverse drug reactions: definitions, diag-nosis, and management. Lancet 2000; 356: 1255-1258.

15) World health organization collaborating centre for international drug monitoring (2007). The importance of pharmacovigilance available at http://www.who_umc.org cited 18December 2007.